Which company produces Mobosetinib/Mobosetinib?

Mobocertinib/Mobocertinib, this innovative drug is developed and produced by Takeda Pharmaceutical Company Limited of Japan. As the world's first oral targeted drug targeting EGFR ex20ins mutations, it plays an important role in the treatment of non-small cell lung cancer (NSCLC).

The R&D code name of Mobotinib isTAK-788. Its Chinese drug names include Mobosetinib Succinate Capsules and Anweili, and its aliases are Mobotinib or Mobosetinib. The drug mainly targets the specific gene target EGFR ex20ins. This target is common in certain subtypes of non-small cell lung cancer, and traditional treatments are often ineffective. The launch of mobotinib provides these patients with new treatment options. In terms of packaging specifications, Mobotinib is usually 40 mg per pill, and each box contains 112 pills, divided into 8 plates, with 14 pills per plate. Such packaging design is not only convenient for patients to take according to dosage, but also convenient for storage and portability.

In an ongoing Phase 1/2 clinical trialthe recommended Phase 2 dose has been determined to be 160 mg once daily. 16 In Phase 1/2 dose escalation and expansion, 28 patients with EGFR Patients with x20ins-mutated NSCLC treated with 160 mg daily had an estimated confirmed objective response rate (ORR) of 43% as of 2020, a median duration of response (mDOR) of 13.9 months, and a median progression-free survival (mPFS) of 7.3 months.

Japan's Takeda Pharmaceutical Company has invested a lot of resources and energy in the research and development process of moboxetinib to ensure the safety and effectiveness of its drug. By cooperating with a number of research institutions and hospitals, Takeda Pharmaceuticals has collected a wealth of clinical data to further verify the clinical application value of moboxetinib. In addition, the company is also actively promoting the launch and promotion of moboxetinib so that it can benefit more patients in need of treatment as soon as possible.

References:https://www.takeda.com/newsroom/newsreleases/2023/takedas-exkivity-mobocertinib-receives-approval-from-the-nmpa-of-china-becoming-the-first-and-only-therapy-available-for-patients-with-egfr-exon20-insertion-nsclc/